Vertex Pharmaceuticals Inc
NASDAQ:VRTX

Watchlist Manager
Vertex Pharmaceuticals Inc Logo
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Watchlist
Price: 408.18 USD 0.72% Market Closed
Market Cap: 105.1B USD
Have any thoughts about
Vertex Pharmaceuticals Inc?
Write Note

P/E
Price to Earnings

-219.3
Current
25
Median
22.1
Industry
Lower than median
Lower than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
-219.3
=
Market Cap
105.2B USD
/
Net Income
-479.8m USD
All Countries
Close
Earnings Growth P/E to Growth
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Average P/E: 214.8
Negative Multiple: -219.3
48%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -181 249.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
62.6
413%
0.2
US
Amgen Inc
NASDAQ:AMGN
33.6
73%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
929.1
77%
12
US
E
Epizyme Inc
F:EPE
Negative Multiple: -471.4 N/A N/A
AU
CSL Ltd
ASX:CSL
32
65%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.9
44%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.6 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -135.8 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -94.3 N/A N/A

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
685.8
2-Years Forward
P/E
21.3
3-Years Forward
P/E
19.6

See Also

Discover More